Scalper1 News
Biotech Intra-Cellular Therapies (ITCI) soared as much as 84% Wednesday after the company announced positive late-stage trial results for its schizophrenia drug. Intra-Cellular said its phase-three study of 450 schizophrenics met the primary endpoint of showing a significant improvement in symptoms among patients taking its drug ITI-007 compared with the placebo group, after four weeks of treatment. The 40 mg dose did not achieve statistical Scalper1 News
Scalper1 News